Chemomab Therapeutics Ltd.
Income Statement
Last updated:
Income statement is a financial statement that shows how profitable a business was over a given reporting period presenting its revenue, expenses or net income. The net income raised on -$24,221,000 over the previous period. Total operating expenses were $25,459,000.
Profit Margin
| 2015 | 0 | -7.50M | |
|---|---|---|---|
| 2017 | 0 | -9.80M | |
| 2018 | 0 | 13.27M | |
| 2019 | 0 | -27.12M | |
| 2020 | 0 | -5.93M | |
| 2021 | 0 | -12.55M | |
| 2022 | 0 | -27.64M | |
| 2023 | 0 | -24.22M |
CMMB Income Statement (2015 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2015 | |
|---|---|---|---|---|---|---|---|---|
Revenue | ||||||||
Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cost of revenue | 66.82K | 57.77K | 34.02K | 79.99K | 281K | 0 | 51K | 26.25K |
Gross profit | -66.82K | -57.77K | -34.02K | -79.99K | -281K | 0 | -51K | -26.25K |
Operating exp. | ||||||||
Research and development | 18.38M | 16.97M | 6.33M | 4.68M | 13.30M | 7.55M | 6.22M | 5.96M |
Selling and marketing | 0 | 0 | 0 | 0 | 5.96M | 0 | 0 | 0 |
Total operating expenses | 25.45M | 28.53M | 12.36M | 5.97M | 19.26M | 13.04M | 9.34M | 7.10M |
Operating income | -25.45M | -28.53M | -12.40M | -5.97M | -19.54M | 12.65M | -9.39M | -7.13M |
Other income (expenses), net | 1.23M | 353K | -77K | 21K | -7.57M | 0 | -164.62K | -367.79K |
Income before tax | -24.22M | -28.18M | -12.47M | -5.95M | -27.12M | 12.65M | -9.48M | -7.50M |
Income tax expense | 0 | -534K | 77K | -21K | 0 | -621K | 323K | -3 |
Net income | -24.22M | -27.64M | -12.55M | -5.93M | -27.12M | 13.27M | -9.80M | -7.50M |
Earnings per share | ||||||||
Basic EPS | -2.06 | -2.43 | -1.21 | -3.2 | -15.75 | 0 | -217.31 | -32.94 |
Diluted EPS | -2.06 | -2.43 | -1.21 | -3.2 | -15.75 | 0 | -217.31 | -32.94 |
| Data source | Data source | Data source | Data source | Data source | Data source |